10x Genomics (NASDAQ:TXG – Get Free Report)‘s stock had its “sell (e+)” rating restated by equities researchers at Weiss Ratings in a note issued to investors on Friday,Weiss Ratings reports.

10x Genomics (NASDAQ:TXG – Get Free Report) had its price target reduced by investment analysts at Citigroup from $20.00 to $15.00 in a note issued to investors on Tuesday,Benzinga reports.

Popcorn is one of my all-time favorite snacks, especially now that I have to eat gluten-free. It's a quick way to fill me up without having to worry about what's in it. Whether it's buttery movie ...

PLEASANTON, Calif., March 3, 2025 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences.

Assets in the region span medtech/medical device development and manufacturing, bioinformatics, genomics, nutrition, human health, clinical research, and, increasingly, biopharma manufacturers.

However, only $17.5 billion, less than half, represents genuine long-only buying, reported 10x Research head of research Markus Thielen. The majority, or around 56%, “is likely tied to arbitrage ...

PLEASANTON, Calif., Feb. 23, 2025 /PRNewswire/ -- At the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology ...

The separator plays a crucial role in the alkaline water electrolysis process, as it fulfills the functions of gas separation and electrolyte transport. Nevertheless, the development of advanced ...